Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity. While demand for these medications has surged globally, causing intermittent supply shortages, patients must obtain them only through legitimate prescriptions to avoid risks associated with counterfeit or unapproved compounded products.
How Ozempic Functions in the Body
Ozempic, manufactured by Novo Nordisk, is an injectable prescription medication approved by the U.S. Food and Drug Administration (FDA) to improve glycemic control in adults with type 2 diabetes. According to the [FDA](https://www.fda.gov/drugs/postmarket-drug-safety-information-regarding-patients-and-drugs/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss), the drug mimics the GLP-1 hormone, which targets areas of the brain that regulate appetite and food intake. By increasing insulin secretion and slowing gastric emptying, the medication helps patients manage blood sugar levels and, in higher doses, promotes weight loss.
Understanding the Current Supply Landscape
The high demand for GLP-1 agonists has led to significant supply chain challenges. Novo Nordisk has acknowledged that periodic shortages occur as they work to expand manufacturing capacity. The [American Society of Health-System Pharmacists (ASHP)](https://www.ashp.org/drug-shortages/current-drug-shortages/drug-shortage-detail.aspx?id=935) maintains updated lists of these shortages, noting that while specific doses may be unavailable at various times, the manufacturer continues to ship product to wholesalers to meet patient needs.
Risks of Counterfeit and Compounded Products
Health authorities have issued warnings regarding unauthorized versions of semaglutide. The [World Health Organization (WHO)](https://www.who.int/news/item/20-06-2024-who-issues-warning-on-falsified-semaglutide-products) issued a medical product alert in 2024 regarding falsified batches of Ozempic found in several countries. These products may contain incorrect ingredients, lack the active pharmaceutical ingredient entirely, or be manufactured in unhygienic conditions.
Furthermore, the FDA emphasizes that “compounded” drugs—custom-mixed versions of a medication—are not FDA-approved. Patients are cautioned that these products may not meet the same standards for safety, effectiveness, or manufacturing quality as the FDA-approved brand-name versions.
Key Considerations for Patients
To ensure safety and efficacy, patients should adhere to the following guidelines:
- Verify the Source: Only obtain medications through state-licensed pharmacies.
- Consult Your Physician: Discuss any difficulty in filling a prescription with a healthcare provider rather than seeking alternative, unverified sources.
- Check for Authenticity: Be wary of online retailers that do not require a prescription or offer prices significantly lower than standard retail costs.
- Report Concerns: If you suspect a product is counterfeit, report it to the [FDA MedWatch program](https://www.accessdata.fda.gov/scripts/medwatch/index.cfm).
Future Outlook
As clinical interest in GLP-1 therapy remains high, both regulators and manufacturers are focused on stabilizing the market. Novo Nordisk continues to invest in production facilities to address the global backlog. Meanwhile, the [European Medicines Agency (EMA)](https://www.ema.europa.eu/en/news/ema-warns-falsified-ozempic-pens) and other international bodies continue to monitor the supply chain to intercept counterfeit products and protect patient health. Patients should remain in close contact with their clinical teams to manage their treatment plans effectively during periods of constrained supply.